// App-Quantinova.ai

562 : Competing risks of mortality by PAM50 intrinsic subtype: BC tamoxifen-treated cohort.

Researchers

Presenter

  • Judy-Anne W. Chapman

Principal Investigators

  • Shuzhen Liu

  • Samuel Leung

  • Torsten O. Nielsen

Medical Centers

  • Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada

  • Vancouver Coastal Health Research Institute and University of British Columbia, Vancouver, BC, CanadaGenetic Pathology Evaluation Centre, Vancouver, BC, CanadaBritish Columbia Cancer Agency, Vancouver, BC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Tamoxifen

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved